FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013885246> ?p ?o ?g. }

• W2013885246 abstract "Interleukin 1 receptor antagonist (IL-1Ra) is a naturally occurring IL-1 inhibitor, acting as a “receptor antagonist”, which blocks IL-1 mediated signal transduction. In 1990 IL-1Ra was cloned and later on, a large numbers of studies led to disclosure of the crucial importance of the imbalance between IL-1 and IL-1Ra in the pathogenesis of rheumatoid arthritis (RA). In 1991, almost 8 years after the initial isolation of IL-1, recombinant IL-1Ra (IL-1ra, Kineret) was introduced in clinical trials involving patients with RA. Between 2001 and 2002 IL-1ra was approved by the US Food and Drug Administration and by the European Agency for the Evaluation of the Medicinal Products and in 2003 it was registered in Italy, too. In RA recombinant IL-1ra has been evaluated in 5 randomized, placebo-controlled clinical trials involving more than 2900 patients. Two of the trials involved the use of IL-1ra as monotherapy versus placebo and two trials in combination with methotrexate (MTX); the last trial explored the use of a fixed 100 mg/day IL-1ra dosage in a RA patient population including a wide array of co-morbid conditions as well as concomitant medications. The studies confirmed both the efficacy and the safety of IL-1ra in patients with active and severe RA. 43% of patients receiving 150 mg/day IL-1ra achieved a 20% response according to the American College of Rheumatology criteria (ACR20), compared to 27% in the placebo group. In the MTX combination therapy study, 42% of the patients receiving 1 mg/Kg/day of IL-1ra achieved an ACR20, 24% an ACR50 and 10% an ACR70. In each study, significant improvements in the Health Assessment Questionnaire scores (HAQ) were observed. There were rapid gains in the number of days at work or domestic activity in the treated patients, and the increases in productivity were dose related. At early 24 weeks, there was significant reduction of both the score for progression of joint space narrowing (JSN) and the Total modified Sharp-Genant score (a combination of erosion and JSN) in all treatment groups (30,75 and 150mg/day). The clinical benefits of treatment with daily subcutaneous injections of IL-1ra in active RA patients were maintained for up to 48 weeks. IL-1ra, a selective inhibitor of the IL-1 pathway, represents an important new biologic approach to treating patients with RA, that significantly reduces clinical signs and symptoms of the disease and joint destruction and has proved safe and well tolerated also in combination with other DMARDs and concomitant medications." @default.
• W2013885246 created "2016-06-24" @default.
• W2013885246 creator A5018858765 @default.
• W2013885246 creator A5023500837 @default.
• W2013885246 creator A5076604631 @default.
• W2013885246 creator A5082141765 @default.
• W2013885246 date "2011-09-12" @default.
• W2013885246 modified "2023-10-01" @default.
• W2013885246 title "IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy" @default.
• W2013885246 doi "https://doi.org/10.4081/reumatismo.2004.1s.62" @default.
• W2013885246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15201942" @default.
• W2013885246 hasPublicationYear "2011" @default.
• W2013885246 type Work @default.
• W2013885246 sameAs 2013885246 @default.
• W2013885246 citedByCount "4" @default.
• W2013885246 countsByYear W20138852462012 @default.
• W2013885246 countsByYear W20138852462018 @default.
• W2013885246 crossrefType "journal-article" @default.
• W2013885246 hasAuthorship W2013885246A5018858765 @default.
• W2013885246 hasAuthorship W2013885246A5023500837 @default.
• W2013885246 hasAuthorship W2013885246A5076604631 @default.
• W2013885246 hasAuthorship W2013885246A5082141765 @default.
• W2013885246 hasBestOaLocation W20138852461 @default.
• W2013885246 hasConcept C126322002 @default.
• W2013885246 hasConcept C142724271 @default.
• W2013885246 hasConcept C149892131 @default.
• W2013885246 hasConcept C170493617 @default.
• W2013885246 hasConcept C204787440 @default.
• W2013885246 hasConcept C27081682 @default.
• W2013885246 hasConcept C2776885963 @default.
• W2013885246 hasConcept C2777077863 @default.
• W2013885246 hasConcept C2777575956 @default.
• W2013885246 hasConcept C2778122271 @default.
• W2013885246 hasConcept C2779384505 @default.
• W2013885246 hasConcept C2781059491 @default.
• W2013885246 hasConcept C2908647359 @default.
• W2013885246 hasConcept C535046627 @default.
• W2013885246 hasConcept C71924100 @default.
• W2013885246 hasConcept C98274493 @default.
• W2013885246 hasConcept C99454951 @default.
• W2013885246 hasConceptScore W2013885246C126322002 @default.
• W2013885246 hasConceptScore W2013885246C142724271 @default.
• W2013885246 hasConceptScore W2013885246C149892131 @default.
• W2013885246 hasConceptScore W2013885246C170493617 @default.
• W2013885246 hasConceptScore W2013885246C204787440 @default.
• W2013885246 hasConceptScore W2013885246C27081682 @default.
• W2013885246 hasConceptScore W2013885246C2776885963 @default.
• W2013885246 hasConceptScore W2013885246C2777077863 @default.
• W2013885246 hasConceptScore W2013885246C2777575956 @default.
• W2013885246 hasConceptScore W2013885246C2778122271 @default.
• W2013885246 hasConceptScore W2013885246C2779384505 @default.
• W2013885246 hasConceptScore W2013885246C2781059491 @default.
• W2013885246 hasConceptScore W2013885246C2908647359 @default.
• W2013885246 hasConceptScore W2013885246C535046627 @default.
• W2013885246 hasConceptScore W2013885246C71924100 @default.
• W2013885246 hasConceptScore W2013885246C98274493 @default.
• W2013885246 hasConceptScore W2013885246C99454951 @default.
• W2013885246 hasIssue "1s" @default.
• W2013885246 hasLocation W20138852461 @default.
• W2013885246 hasLocation W20138852462 @default.
• W2013885246 hasLocation W20138852463 @default.
• W2013885246 hasLocation W20138852464 @default.
• W2013885246 hasOpenAccess W2013885246 @default.
• W2013885246 hasPrimaryLocation W20138852461 @default.
• W2013885246 hasRelatedWork W1592252953 @default.
• W2013885246 hasRelatedWork W2101525442 @default.
• W2013885246 hasRelatedWork W2136668366 @default.
• W2013885246 hasRelatedWork W2153748057 @default.
• W2013885246 hasRelatedWork W2160902968 @default.
• W2013885246 hasRelatedWork W2328985364 @default.
• W2013885246 hasRelatedWork W2341338148 @default.
• W2013885246 hasRelatedWork W2403613669 @default.
• W2013885246 hasRelatedWork W2410629868 @default.
• W2013885246 hasRelatedWork W2602481810 @default.
• W2013885246 hasVolume "56" @default.
• W2013885246 isParatext "false" @default.
• W2013885246 isRetracted "false" @default.
• W2013885246 magId "2013885246" @default.
• W2013885246 workType "article" @default.